Abstract:Background Despite the significant impact of pharmaceutical innovations on healthcare, our understanding is still limited because previous studies explored only a few cases and largely came from a linear perspective. This study presents a detailed case of the Chinese and U.S. pharmaceutical patents and investigated advancements that the global pharmaceutical industry is experiencing. A network analysis approach was used to identify certain aspects regarding the diffusion of pharmaceutical innovations, including innovation attributes, adopter characteristics, and clustering. Methods Based on a patent database, network analysis and visualization, this study captured the structure of patent networks for the global pharmaceutical landscape in a large set of patents. A large volume of patent data, 15,422 patent filings citing Chinese pharmaceutical patents, 28,075 citing U.S. patents, and 6064 citing both Chinese and U.S. patents during 2014–2015, were retrieved from the world patent database, Derwent Innovation Index . The networks reveal many interesting features of technological innovation, convergence trends and diffusion patterns. Results Convergence innovations were identified, with the advantage and influence of U.S. patents shown in a variety of areas, and their Chinese counterparts were concentrated in traditional Chinese medicine. Early adopters of Chinese patents were mainly universities within the national sector, while early adopters of U.S. patents were academic institutions and large international pharmaceutical corporations of balanced quantity, contributing a higher degree of technology convergence. Technology convergence in the cancer-treatment sector is expected to have a high future development potential. Conclusion Chinese and U.S. pharmaceutical innovations contributed differently to the growth and development of the global pharmaceutical industry. The findings of this study can provide rich knowledge about the influence, diffusion and convergence trends of Chinese and U.S. pharmaceutical innovations. In the pharmaceutical industry, the findings may provide implications for researchers, policy makers, health professionals, and the general public to help improve the overall health of society.

Primary Investigation of the Indicators of Quality Evaluation on the Chinese Drug Patent

[Research on evaluation criteria over quality as core index of high grade Chinese patent medicine]

Research of Present Domestic Situation on Off-patent Originals and Generics

Research advances in secondary development of Chinese patentmedicines based on quality by design concept

Research on the Classification Evaluation of Patent Quality and Empirical Test

Quantitative evaluation of the medicine innovation policy in China: based on the PMC-Index model

Exploratory study on performance evaluation of drug administration at provincial level in China

Evaluating R&D Effectiveness: a Study on Chinese Practice and Trend

The Impact of Intellectual Property Quality on Economic Development: Insights from Jiangsu Province

Intellectual Property Rights Protection and Quality Upgrading: Evidence from China

CHINA’S HIGH-QUALITY INNOVATION DEVELOPMENT FROM AN INSTITUTIONAL PERSPECTIVE: REGIONAL DIFFERENCES AND CONVERGENCE

Study on Enterprise Strategies for the Evaluation of Quality and Efficacy Consistency of Generic Drugs

International Performance of Chinese Institutes in Different Disciplines——A Bibliometric View

[Expert consensus on core indicators for lifecycle value assessment of Chinese patent medicine]

Establishment of Drug Safety Performance Evaluation Indicator System for Work Quality Evaluation of Drug Administration Department

Does Firm's Value Matter With Firm's Patent Quality in Technology-Intensive Industries?

An Analysis of the Impact of Traditional Chinese Culture on Patent Output Quality in China

[Guidelines for Economic Evaluation of Post-Marketing Chinese Patent Medicine].

Systems analysis and evaluation of Chinese pharmacoeconomic literatures over ifve years

[Report standards for clinical comprehensive evaluation of Chinese patent medicine]

Diffusion, Convergence and Influence of Pharmaceutical Innovations: a Comparative Study of Chinese and U.S. Patents.